Restoration of miR-185 expression reduces the burden of leukemia and sensitizes leukemic blast cells to TKI treatment, with enhanced survival of leukemic mice. (A) Schematic of the experimental design. BV173^YFP/Luc cells transduced with a miR-185-expressing vector, or a pRRL control vector, were injected intravenously into sublethally irradiated nonobese diabetic/severe combined immunodeficiency IL2Rγ-chain–deficient (NSG) mice (2.5 × 10⁶ cells per mouse). Two weeks later, a daily oral gavage treatment of 15 mg/kg DA or vehicle (propylene glycol) was initiated for another 2 weeks. (B) Bioluminescence images of mice taken 2 weeks posttransplantation, before initiation of the oral gavage treatment. (C) Representative bioluminescence images of mice from each group taken 7 weeks posttransplantation. One mouse from each group was then sacrificed to obtain images and weights of spleens and livers. (D) FACS profiles showing human leukemic cell chimerism (GFP⁺ and YFP⁺) in PB, BM, spleen, and liver from mice in each group. (E) Representative hematoxylin and eosin-stained sections of spleens and livers from all treatment groups. (F) Fold-difference in BCR-ABL1 transcripts in hematopoietic tissues from each group. Data shown are mean ± SEM of measurements from 3 technical replicates. P values were calculated using a 2-tailed paired Student t test. (G) Western blots of whole protein extracted from BM cells of mice in each group, after probing with the antibodies indicated. (H) Overall survival of mice from each treatment group (n = 6 mice per group). P values were calculated using log-rank test. ND = not detectable.